eXoZymes, Inc. (EXOZ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
eXoZymes, Inc. (EXOZ) trades at $7.15 with AI Score 32/100 (Grade D). eXoZymes, Inc. is a synthetic biochemical company focused on developing the SimplePath platform. Market cap: $66.4M, Sector: Healthcare.
Price as of Aug 22, 2026 · Last analyzed: May 9, 2026Analyst Coverage for EXOZ: EXOZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EXOZ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EXOZ: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
eXoZymes, Inc. (EXOZ) Healthcare & Pipeline Overview
eXoZymes, Inc. is a synthetic biochemical company specializing in the development of the SimplePath platform. This platform is designed for the production of diverse chemicals, including pharmaceuticals, fuels, materials, and food additives, positioning the company within the biotechnology sector.
What Is the Investment Thesis for EXOZ?
eXoZymes, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's SimplePath platform has the potential to disrupt traditional chemical manufacturing processes, offering a more sustainable and efficient alternative. Key value drivers include the successful development and commercialization of SimplePath for various applications, such as pharmaceuticals, fuels, and food additives. The company's small market capitalization of $66.4M reflects its early stage of development. Growth catalysts include securing partnerships with established companies in the chemical and pharmaceutical industries and achieving regulatory approvals for its products. Potential risks include the company's reliance on its SimplePath platform, competition from established chemical manufacturers, and the need for significant capital investment to scale up production.
Based on FMP financials and quantitative analysis
EXOZ Key Highlights
eXoZymes, Inc. operates as a synthetic biochemical company focused on developing the SimplePath platform.
- The SimplePath platform is designed to produce a wide array of chemicals, including pharmaceuticals, fuels, materials, and food additives.
- The company was founded in 2014 and is headquartered in Monrovia, California.
- The company has a market capitalization of $66.4M.
- eXoZymes employs 31 people.
Who Are EXOZ's Competitors?
EXOZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.83 | +1.39% | $89.3M | 81 |
| ICCC ImmuCell Corporation | $10.06 | -0.30% | $91.0M | 78 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.81 | +0.42% | $197M | 77 |
| CGEN Compugen Ltd. | $2.62 | -1.32% | $247M | 76 |
| NAGE Niagen Bioscience Inc | $3.21 | +1.90% | $256M | 74 |
| QTTB Q32 Bio Inc. | $15.97 | +0.69% | $475M | 83 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EXOZ's Key Strengths?
Innovative SimplePath platform.
- Potential for sustainable chemical production.
- Expertise in biocatalysis.
- Focus on diverse chemical applications.
What Are EXOZ's Weaknesses?
Early stage of development.
- Limited financial resources.
- Small team size.
- Reliance on a single platform technology.
What Could Drive EXOZ Stock Higher?
Securing partnerships with pharmaceutical or chemical companies to validate and scale the SimplePath platform.
- Achieving regulatory milestones for SimplePath-produced chemicals in key markets.
- Continued development and optimization of the SimplePath platform for various applications.
- Expansion of the company's intellectual property portfolio through patent filings.
What Are the Key Risks for EXOZ?
Financial-distress signal — its Altman Z-Score of 0.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure partnerships or funding to support the development and commercialization of the SimplePath platform.
- Competition from established chemical manufacturers with greater resources and market share.
- Regulatory hurdles and delays in obtaining approvals for SimplePath-produced chemicals.
- Technological challenges in scaling up the SimplePath platform for mass production.
What Are the Growth Opportunities for EXOZ?
- Expansion into the pharmaceutical sector: eXoZymes has the opportunity to leverage its SimplePath platform to produce pharmaceutical ingredients and novel drug compounds. The global pharmaceutical market is a multi-billion dollar industry, with a growing demand for innovative and cost-effective manufacturing processes. By partnering with pharmaceutical companies, eXoZymes can gain access to this lucrative market and generate significant revenue. The timeline for this growth opportunity is dependent on securing partnerships and achieving regulatory approvals, potentially within the next 3-5 years.
- Development of sustainable fuels: The SimplePath platform can be utilized to produce biofuels and other sustainable fuels, addressing the growing demand for renewable energy sources. eXoZymes can capitalize on this trend by developing partnerships with energy companies and demonstrating the economic viability of its biofuel production process. This growth opportunity could materialize within the next 5-7 years, depending on technological advancements and market conditions.
- Production of food additives: eXoZymes can expand its SimplePath platform to produce food additives and ingredients, catering to the growing demand for natural and sustainable food products. The global food additives market is a multi-billion dollar industry, with increasing consumer preference for healthier and more environmentally friendly options. By developing partnerships with food manufacturers, eXoZymes can gain access to this market and generate revenue. This growth opportunity could be realized within the next 3-5 years, depending on regulatory approvals and market acceptance.
- Licensing of the SimplePath platform: eXoZymes can generate revenue by licensing its SimplePath platform to other companies in the chemical, pharmaceutical, and food industries. This would allow other companies to utilize the technology for their own production processes, while eXoZymes receives licensing fees and royalties. The market for biotechnology licensing is substantial, with numerous companies seeking innovative technologies to improve their manufacturing processes. This growth opportunity could be pursued in the near term, potentially within the next 1-2 years.
- Development of novel compounds: The SimplePath platform can be used to create novel compounds with unique properties and applications. This could lead to the development of new materials, pharmaceuticals, and other products with significant commercial potential. The market for novel compounds is vast and diverse, with opportunities in various industries. eXoZymes can pursue this growth opportunity by investing in research and development and collaborating with universities and research institutions. This is a longer-term growth opportunity, potentially materializing within the next 5-10 years.
What Are EXOZ's Competitive Advantages?
- Proprietary SimplePath platform technology.
- Expertise in enzyme engineering and biocatalysis.
- Potential for cost-effective and sustainable chemical production.
- Early mover advantage in the synthetic biochemical space.
What Does EXOZ Do?
Founded in 2014 and headquartered in Monrovia, California, eXoZymes, Inc. is a synthetic biochemical company focused on revolutionizing the production of chemicals. The company's core technology is the SimplePath platform, an innovative system designed to produce a wide array of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. SimplePath utilizes modules, each containing enzymes that work synergistically to perform specific biocatalytic conversions. This modular approach allows for flexibility and customization in chemical production, potentially leading to more efficient and sustainable manufacturing processes. eXoZymes aims to disrupt traditional chemical synthesis methods by offering a more environmentally friendly and cost-effective alternative. The company is still in the early stages of commercialization, focusing on developing and refining its SimplePath platform for various applications. With a small team of 31 employees, eXoZymes is dedicated to advancing its technology and expanding its market reach within the biotechnology sector.
What Products and Services Does EXOZ Offer?
- Develops the SimplePath platform for chemical production.
- Produces chemicals including pharmaceuticals, fuels, materials, and food additives.
- Utilizes enzymes to perform biocatalytic conversions.
- Offers a sustainable alternative to traditional chemical synthesis.
- Aims to disrupt the chemical manufacturing industry.
- Focuses on developing and refining its SimplePath platform.
How Does EXOZ Make Money?
- Develops and licenses the SimplePath platform.
- Produces and sells chemicals manufactured using the SimplePath platform.
- Partners with companies in the pharmaceutical, fuel, and food industries.
- Generates revenue through licensing fees, royalties, and product sales.
What Industry Does EXOZ Operate In?
eXoZymes, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation and significant growth potential. eXoZymes' focus on developing a sustainable and efficient chemical production platform aligns with the growing demand for environmentally friendly manufacturing processes. The company faces competition from established chemical manufacturers and other biotechnology companies developing alternative chemical synthesis methods. Success in this competitive landscape will depend on eXoZymes' ability to demonstrate the superior performance and cost-effectiveness of its SimplePath platform.
Who Are EXOZ's Key Customers?
- Pharmaceutical companies seeking efficient manufacturing processes.
- Energy companies looking for sustainable fuel production methods.
- Food manufacturers requiring natural and sustainable food additives.
- Chemical companies interested in licensing the SimplePath platform.
Company Profile
eXoZymes, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Monrovia, US. The company is led by CEO Michael Heltzen. EXOZ has traded publicly since 2024.
Financial Health
eXoZymes, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.65 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -9.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.6%, the inverse of the P/E and a quick read on earnings relative to price.
EXOZ Valuation & Market Position
With a $66.4M market cap, eXoZymes, Inc. sits in the micro-cap segment of the market. Relative to its peer group, EXOZ's quantitative score of 32/100 is below the peer average of 77/100.
EXOZ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying has increased, indicating confidence from leadership in the company's future prospects.
- Recent community sentiment has shifted positively, with more discussions around product innovations and potential partnerships.
- Analysts are noting the growing demand for biotechnological solutions, which aligns with eXoZymes' core offerings.
- The company has been actively engaging with its user base on social platforms, fostering a sense of community and support.
Bear Case
- Concerns about competition in the biotech sector have been prevalent, with some investors wary of eXoZymes' market position.
- Recent social sentiment has shown skepticism regarding the scalability of their product applications.
- There are whispers of regulatory challenges that could impact product launches, causing unease among investors.
- Market perception remains cautious as some community members express doubts about the company's long-term growth strategy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EXOZ Latest News
No recent news available for EXOZ.
EXOZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EXOZ.
Price Targets
Wall Street price target analysis for EXOZ.
EXOZ MoonshotScore
What does this score mean?
The MoonshotScore rates EXOZ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael Heltzen
CEO
Michael Heltzen is the CEO of eXoZymes, Inc., leading a team of 31 employees. His background includes experience in managing and scaling technology-driven companies. He has a proven track record of driving innovation and commercializing new technologies. Heltzen's expertise lies in strategic planning, business development, and team leadership. He is focused on advancing eXoZymes' SimplePath platform and expanding the company's market reach within the biotechnology sector.
Track Record: Under Michael Heltzen's leadership, eXoZymes, Inc. has focused on developing and refining its SimplePath platform. He has overseen the company's efforts to secure partnerships and explore new market opportunities. Heltzen's strategic decisions have been instrumental in positioning eXoZymes as a potential disruptor in the chemical manufacturing industry.
EXOZ Healthcare Stock FAQ
What does the AI Score mean for EXOZ?
EXOZ holds an AI Score of 32/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. eXoZymes, Inc. is a synthetic biochemical company focused on developing the SimplePath platform. This platform aims to produce a variety of chemicals, including pharmaceuticals, fuels, and food …
What does eXoZymes, Inc. do?
eXoZymes, Inc. is a synthetic biochemical company that develops and commercializes the SimplePath platform. This platform is designed to produce a wide range of chemicals, including pharmaceuticals, fuels, materials, and food additives, using a more sustainable and efficient process than traditional chemical synthesis.
What do analysts say about EXOZ stock?
As of May 9, 2026, there is limited analyst coverage available for eXoZymes, Inc. (EXOZ), likely due to its small market capitalization and early stage of development. Key valuation metrics are difficult to assess without significant revenue generation.
What are the main risks for EXOZ?
eXoZymes, Inc. faces several key risks, including its reliance on the SimplePath platform, competition from established chemical manufacturers, and the need for significant capital investment. The company's success depends on the successful development and commercialization of its platform, which may face technological challenges and regulatory hurdles. Furthermore, eXoZymes competes with larger companies that have greater resources and market share.
How does eXoZymes, Inc. navigate regulatory approval processes?
eXoZymes, Inc. faces the challenge of navigating complex regulatory approval processes, particularly for its pharmaceutical and food additive applications. The company must comply with regulations set by agencies such as the FDA in the United States. Its strategy involves rigorous testing and validation of its SimplePath-produced chemicals to ensure safety and efficacy.
What revenue streams does eXoZymes, Inc. have in healthcare?
Currently, eXoZymes, Inc. does not have established revenue streams in the healthcare sector. The company's primary focus is on developing the SimplePath platform and securing partnerships with pharmaceutical companies. Potential revenue streams in the future could include the production and sale of pharmaceutical ingredients, licensing of the SimplePath platform to pharmaceutical manufacturers, and the development of novel drug compounds.
What are the key factors to evaluate for EXOZ?
eXoZymes, Inc. (EXOZ) holds an AI score of 32/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does EXOZ data refresh on this page?
EXOZ's price was last updated on Aug 22, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EXOZ's recent stock price performance?
eXoZymes, Inc. (EXOZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative SimplePath platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Financial metrics are estimates based on current market conditions.
- Future performance is subject to various risks and uncertainties.